NASDAQ:NCNA NuCana (NCNA) Stock Price, News & Analysis $1.28 0.00 (0.00%) Closing price 09/25/2026 04:00 PM EasternExtended Trading$1.29 +0.01 (+0.78%) As of 09/25/2026 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsNews and TrendsOwnershipSEC Filings About NuCana Stock (NASDAQ:NCNA) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get NuCana alerts:Sign Up Key Stats Today's Range$1.21▼$1.3550-Day Range$1.21▼$1.7652-Week Range$1.21▼$7.22Volume38,172 shsAverage Volume40,027 shsMarket Capitalization$5.32 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingSell Company Overview NuCana plc is a clinical-stage biopharmaceutical company focused on developing cancer treatments designed to improve the delivery and activity of nucleoside analog medicines. The company’s proprietary ProTide technology is intended to help overcome biological barriers that can limit the effectiveness of conventional nucleoside-based therapies. NuCana’s lead investigational product, NUC-3373, is a ProTide-based therapy derived from 5-fluorouracil (5-FU), a commonly used chemotherapy agent. The company has evaluated NUC-3373 in clinical studies involving patients with advanced solid tumors, including colorectal cancer. NuCana has also developed NUC-7738, an investigational ProTide compound derived from the nucleoside analog 3'-deoxyadenosine, for potential use in oncology and immuno-oncology applications. NuCana was founded in the United Kingdom and has conducted research and clinical development activities through international collaborations and studies. The company has been led by Chief Executive Officer Hugh Griffith, one of its founders. Its development programs remain focused on advancing novel cancer therapies through clinical testing and potential regulatory approval.AI Generated. May Contain Errors. Read More NuCana Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks27th Percentile Overall ScoreNCNA MarketRank™: NuCana scored higher than 27% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion0.7 / 5Analyst RatingSell Consensus RatingNuCana has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.Amount of Analyst CoverageNuCana has only been the subject of 1 research reports in the past 90 days.Read more about NuCana's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of NuCana is -0.34, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of NuCana is -0.34, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioNuCana has a P/B Ratio of 0.17. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about NuCana's valuation and earnings. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted3.74% of the float of NuCana has been sold short.Short Interest Ratio / Days to CoverNuCana has a short interest ratio ("days to cover") of 2.62, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in NuCana has recently decreased by 32.49%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldNuCana does not currently pay a dividend.Dividend GrowthNuCana does not have a long track record of dividend growth. News and Social Media3.6 / 5News SentimentN/A News SentimentNuCana has a news sentiment score of 1.79. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.74 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 1 news article for NuCana this week, compared to 1 article on an average week.MarketBeat Follows3 people have added NuCana to their MarketBeat watchlist in the last 30 days. Company Ownership1.2 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, NuCana insiders have not sold or bought any company stock.Percentage Held by Insiders31.20% of the stock of NuCana is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions44.00% of the stock of NuCana is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about NuCana's insider trading history. Receive NCNA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for NuCana and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. NCNA Stock News HeadlinesNuCana Files Q2 2026 Results and Updates U.S. Registration StatementsAugust 16, 2026 | theglobeandmail.comNuCana Reports Second Quarter 2026 Financial Results and Provides Business UpdateAugust 13, 2026 | globenewswire.comFirst Look: Elon’s “Starphone”Rumors are swirling that Elon Musk is developing a new mobile device that could rival the iPhone. It's said to be thinner, longer-lasting on battery, and cheaper to produce, with the ability to work worldwide without relying on cell towers. Former Bloomberg reporter and SAC Capital trader Josh Baylin says the evidence is mounting. He notes the FCC recently gave Musk a green light connected to his mobile plans, adding fuel to speculation. Baylin previously called the smartphone boom in 2004 and predicted Apple would sell a billion phones when others expected a fraction of that. | Stansberry Research (Ad)NuCana plc Sponsored ADRJune 16, 2026 | edition.cnn.comNuCana Appoints Ian Webster as Chief Financial OfficerJune 1, 2026 | globenewswire.comNuCana Reports First Quarter 2026 Financial Results and Provides Business UpdateMay 14, 2026 | globenewswire.comNuCana Posts 2025 Results, Highlights NUC-7738 Progress and Cash Runway Into 2029March 22, 2026 | theglobeandmail.comNuCana Reports Fourth Quarter and Year-End 2025 Financial Results and Provides Business UpdateMarch 19, 2026 | globenewswire.comSee More Headlines NCNA Stock Analysis - Frequently Asked Questions How have NCNA shares performed this year? NuCana's stock was trading at $3.60 at the beginning of 2026. Since then, NCNA shares have decreased by 64.4% and is now trading at $1.28. How were NuCana's earnings last quarter? NuCana PLC Sponsored ADR (NASDAQ:NCNA) issued its quarterly earnings data on Thursday, August, 13th. The company reported ($0.99) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($2.65) by $1.66. When did NuCana's stock split? NuCana shares reverse split on the morning of Friday, August 8th 2025.The 1-200 reverse split was announced on Friday, July 11th 2025. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, August 7th 2025. An investor that had 100 shares of stock prior to the reverse split would have 1 shares after the split. When did NuCana IPO? NuCana (NCNA) raised $100 million in an IPO on Thursday, September 28th 2017. The company issued 6,667,000 shares at $14.00-$16.00 per share. Citigroup, Jefferies and Cowen served as the underwriters for the IPO and William Blair was co-manager. How do I buy shares of NuCana? Shares of NCNA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of NuCana own? Based on aggregate information from My MarketBeat watchlists, some other companies that NuCana investors own include VBI Vaccines (VBIV), Anavex Life Sciences (AVXL), Sorrento Therapeutics (SRNE), Plug Power (PLUG), SCYNEXIS (SCYX), CRISPR Therapeutics (CRSP). Company Calendar Last Earnings8/13/2026Today9/27/2026Next Earnings (Estimated)11/12/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (6m+) 1-Year History Sep 25 Dec 25 Mar 26 Jun 26 Sep 26 NCNA's financial health is in the Red zone, according to TradeSmith. NCNA has been in this zone for over 6 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNASDAQ:NCNA CIK1709626 Webwww.nucana.com Phone441313571111FaxN/AEmployees11Year Founded2008Profitability EPS (Trailing Twelve Months)($3.81) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$38.71 million Net MarginsN/A Pretax MarginN/A Return on Equity-41.90% Return on Assets-33.69% Debt Debt-to-Equity RatioN/A Current Ratio4.73 Quick Ratio4.73 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$7.71 per share Price / Book0.17Miscellaneous Outstanding Shares4,160,000Free Float2,863,000Market Cap$5.32 million OptionableNot Optionable Beta2.23 Social Links 7 Stocks That Could Lead the Next Market BoomTesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.Get This Free Report This page (NASDAQ:NCNA) was last updated on 9/28/2026 by MarketBeat.com Staff. From Our Partners"How Much Can I Actually Spend Each Year With $2.5M Saved?"Having $2.5 million saved puts you ahead of most Americans, but how long it lasts depends on the decisions you...SmartAsset | SponsoredMusk says UBI is coming. I say it's already here.Elon Musk says AI could make money irrelevant by 2036. One income program already exists today, funded not by ...Freedom Financial | SponsoredWhy major institutions are piling into this digital asset nowBlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...Awesomely | SponsoredTrump's New DollarPorter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. doll...Porter & Company | SponsoredCODE RED: AI Meltdown Imminent?After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...Paradigm Press | SponsoredThis AI Stock Reminds One Analyst of Early NvidiaJeff Brown picked Nvidia in 2016, before shares surged 37,800 percent. Now he's identified another AI company ...Brownstone Research | SponsoredDo NOT Buy SpaceX – Do This InsteadSpaceX just went public - and Whitney Tilson, Harvard MBA and 30-year Wall Street veteran, says buying in coul...Stansberry Research | SponsoredIgnore oil - This is the Energy Story of the century…A drilling crew in Utah punched through three miles of granite in 16 days, a job the Department of Energy said...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NuCana PLC Sponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share NuCana With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
